PL6 New Genetic Insights into the Pathogenesis and Treatment of Thyroid Cancer

Program: Plenary
Translational Session
Sunday, April 3, 2016: 3:30 PM-4:30 PM
Hall B2 (BCEC)

Thyroid genetics catches up to physiology:  Out of two early Nobels for thyroid physiology and surgery, the new genomics of thyroid cancer hit the clinic.

3:30 PM
Lisa H Fish, MD, Hennepin County Medical Ctr, Edina, MN
Nothing to Disclose: LHF
3:40 PM
Matthew D Ringel, MD, The Ohio State University, Columbus, OH
Nothing to Disclose: MDR
4:05 PM
Barbara Maria Jarzab, MD, PhD, Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland
Nothing to Disclose: BMJ
See more of: Plenary

 

The Endocrine Society would like to thank the following organizations for their support: AbbVie Inc.; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Chiasma, Inc.; Corcept Therapeutics Incorporated; Eisai, Inc.; Ethicon Endo-Surgery, Inc.; Genzyme, a Sanofi company, Ipsen Biopharmaceuticals, Inc.; Leona M. and Harry B. Helmsley Charitable Trust; Lilly USA, LLC; Medtronic Diabetes; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Pfizer, Inc.; Shire